Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA.
Am J Transplant. 2011 May;11(5):1079-84. doi: 10.1111/j.1600-6143.2011.03530.x.
We report the first case of cytomegalovirus (CMV) disease treated with AIC246, a novel anti-CMV compound which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors. A lung transplant recipient developed refractory multidrug-resistant CMV disease involving the lungs, gastrointestinal tract and retina. His disease progressed despite treatment with all DNA polymerase inhibitors; multiple agents reported to have activity against CMV in case series, and reduction in his immunosuppressive medications. AIC246 which is in clinical development was obtained for emergency use, and combined with additional reduction in immunosuppression resulted in rapid clinical, virological and radiological resolution of disease. The patient has remained free of CMV disease or viremia off treatment for greater than 3 months. In summary AIC246, while still in development, may be a promising alternative to current therapies.
我们报告了首例使用 AIC246 治疗的巨细胞病毒 (CMV) 疾病病例。AIC246 是一种新型抗 CMV 化合物，针对病毒终止酶复合物，对 DNA 聚合酶抑制剂耐药的病毒仍然有效。一名肺移植受者发生了涉及肺部、胃肠道和视网膜的难治性多药耐药 CMV 疾病。尽管他接受了所有 DNA 聚合酶抑制剂的治疗，疾病仍在进展；在病例系列中，有多种药物被报道对 CMV 具有活性，而且他的免疫抑制剂药物也减少了。正在临床开发中的 AIC246 被紧急用于治疗，与额外减少免疫抑制相结合，导致疾病的临床、病毒学和影像学迅速缓解。该患者在停药后 3 个月以上未出现 CMV 疾病或病毒血症。总之，AIC246 虽然仍在开发中，但可能是目前治疗方法的一个有前途的替代方案。
